Research
Hormonal
Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major renal events, cardiovascular death, and all-cause death in patients with type 2 diabetes and chronic kidney disease.
If you have type 2 diabetes and chronic kidney disease, ask your doctor about weekly semaglutide injections. This treatment has been shown to significantly slow the progression of kidney disease and reduce the risk of heart-related death and overall death, offering strong protection for your kidneys and heart.
StrongSupportsVERY_HIGH confidence
The primary renal endpoints were reduced by 24% (hazard ratio 0.76, 95% confidence interval 0.66-0.88). The cardiovascular death and all-cause death were also significantly reduced (hazard ratio 0.71, 95% confidence interval 0.56-0.89; hazard ratio 0.80, 95% confidence interval 0.67-0.95).
Why this rating
Based on the FLOW trial, a large-scale randomized clinical trial.
Source
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health
Chern-En Chiang et al. · Journal of the Chinese Medical Association · 2025
narrative_reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →